Back to List View Graph View

Ustekinumab

Ustekinumab is a therapeutic monoclonal antibody used in immune-mediated inflammatory diseases.

Where the papers sit

9 papers from the last 6 months study ustekinumab directly · updated from PubMed 13 Nov 2026

Study type 0 clinical trials · 1 observational · 2 human data · 6 unclassified

Themes one subject

Those 9 are all about one subject.

  • Crohn's Disease Treatment

    Advanced therapies are being compared increasingly through real-world effectiveness, safety, persistence, and quality-of-life outcomes in Crohn's disease. Ustekinumab is positioned alongside anti-TNF agents and vedolizumab for biologic-naive patients, with treatment selection and durability as recurring questions. Biosimilar switching is moving toward clinical normalization, while partial enteral nutrition is being tested as an adjunct to induction and maintenance. Pediatric evidence, long-term comparative outcomes, and determinants of persistence remain important gaps.

    9 papers

Papers

The 9 papers from the last 6 months that study ustekinumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Crohn's Disease Treatment (9)
  1. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
  2. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  3. Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 3 Oct 2026 PMID 42829277
  4. Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 27 Aug 2026 PMID 42660257
  5. Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort. Clinical nutrition (Edinburgh, Scotland) · 10 Jul 2026 PMID 42430976
  6. Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Alimentary pharmacology & therapeutics · 10 Jul 2026 PMID 42426976
  7. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
  8. Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany. Alimentary pharmacology & therapeutics · 15 Jun 2026 PMID 42298310
  9. Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab. Drug delivery · 29 May 2026 PMID 42212686

By study type

Observational studies and case reports (1)
  1. Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD). Journal of Crohn's & colitis · 7 Nov 2026 PMID 42998010
Human data, design not indexed (2)
  1. Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort. Clinical nutrition (Edinburgh, Scotland) · 10 Jul 2026 PMID 42430976
  2. Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab. Drug delivery · 29 May 2026 PMID 42212686
Unclassified: not yet indexed with MeSH (6)
  1. Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
  2. Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 3 Oct 2026 PMID 42829277
  3. Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 27 Aug 2026 PMID 42660257
  4. Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Alimentary pharmacology & therapeutics · 10 Jul 2026 PMID 42426976
  5. Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
  6. Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany. Alimentary pharmacology & therapeutics · 15 Jun 2026 PMID 42298310